Ex-Pfizer researchers bag $27m for ‘not-a-Pfizer-spin-out’

"This is not a Pfizer spin out," insists Dr Mike Yeadon CEO of new biotech company Ziarco, which has licensed inflammatory and allergic therapeutic candidates from Pfizer and secured a $27 million series A round led by Biotechnology Value Fund and including Pfizer Venture Investments.